All News
Conaghan: "Most promising study in OA" at #RNL2023
NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated?
Can there be sustained response.
Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪
@RheumNow https://t.co/eBMEPBG9wn
Eric Dein ericdeinmd ( View Tweet)
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/2Y5am2YEsQ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Conaghan shares unpublished data from PROMOTE study at #RNL2023
Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active.
Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA
@RheumNow https://t.co/Ieagp8mq31
Eric Dein ericdeinmd ( View Tweet)
30% rule!
Risk of RA development in Pre clinical RA patient in the next 3 to 5 years .
Kevin Deane #RNL2023 @RheumNow https://t.co/J6Polz70im
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr Philip Conaghan at #RNL2023
X-rays are misleading in OA
OA is a CLINICAL disease
Radiographs do not help in diagnosis or monitoring
@RheumNow https://t.co/ZrAfPN02qi
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/zJRRisGW9i
Eric Dein ericdeinmd ( View Tweet)
@RheumNow Live #RNL2023
Stanley Cohen, MD:
Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16
ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG
Eric Dein ericdeinmd ( View Tweet)
Dr Brenner at #RNL2023
Excellent description on how fibroblasts are major producers of IL-6 producers
Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA
@RheumNow https://t.co/TserFZtvhV
Eric Dein ericdeinmd ( View Tweet)
JAKinib safety takeaways
- avoid in older population > 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/5i1bRqqr7g
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow Live 2023 Starts Tomorrow!
Or does it start earlier?
Love that there is a pre-learn and pre-test to set the stage for #RNL2023
Excited for this talk by @anisha_dua on assessment for GCA/PMR
#RheumTwitter https://t.co/VcawlnaPFf
Eric Dein ericdeinmd ( View Tweet)
Faith and Miracle Larry
This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020.
https://t.co/SfidfBF1En https://t.co/Jnv6moxYwQ
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/AZDKShOPbU
Eric Dein ericdeinmd ( View Tweet)
Dr. Deanne reminds us that RA is worth preventing for many reasons. #RNL2023 @RheumNow https://t.co/va0RmdhUQR
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Kevin Deane on preclinical-RA
Very complex history on development of RA with multiple phases before detectable RA shows up in your clinic.
#RNL2023 @RheumNow https://t.co/vzQFhik0aK
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023:
Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years
@RheumNow https://t.co/skp1K4r1hF
Eric Dein ericdeinmd ( View Tweet)
STOP-RA study on HCQ preventing RA...
HCQ did NOT prevent RA development in pre-RA pts
@RheumNow #RNL2023 https://t.co/Vv3szkqxWh
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 @RheumNow
Kevin Deane presents his STOP RA Trial
HCQ is safe and easy - can you use it in pre-clinical RA to prevent disease?
NO EVIDENCE of decreased progression of RA in HCQ compared to placebo https://t.co/1OSVubd9rO
Eric Dein ericdeinmd ( View Tweet)
Treatment with MTX in early CCP+ RA thought to be effective in slowing disease however StopRA study did not show a difference between HCQ and PBO in patients. We need to know more about HCQ vs MTX in this space! #RNL2023 @RheumNow https://t.co/7asmvVfXiC
Dr. Rachel Tate uptoTate ( View Tweet)
The holy grail. How to stop #rheumatoid #arthritis in at risk Pts. Who to treat, when to stop? Many RCTs but no home run-NNT is high. #MTX and a diff study #Abatacept that work while on Rx and #Rituximab, most don’t work esp after stopping Rx @kevindeane #RNL23 @RheumNow https://t.co/BkIxxS0ecn
Janet Pope Janetbirdope ( View Tweet)
Dr. Deane's current management of "pre-RA" pts
- carefully eval for synovitis
- lifestyle factors - stop smoking, diet, dental hygiene
- educate pt on ~30% risk
- annual in-person follow up
@RheumNow #RNL2023 https://t.co/Z0t0Yibyri
Robert B Chao, MD doctorRBC ( View Tweet)